Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases
Abstract Siglec-15 is a member of the Siglec family of glycan-recognition proteins, primarily expressed on a subset of myeloid cells. Siglec-15 has been known to be involved in osteoclast differentiation, and is considered to be a potential therapeutic target for osteoporosis. Recent studies reveale...
Main Author: | Takashi Angata |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | Journal of Biomedical Science |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12929-019-0610-1 |
Similar Items
-
Siglecs as Therapeutic Targets in Cancer
by: Jackwee Lim, et al.
Published: (2021-11-01) -
Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs
by: Takashi Angata
Published: (2018-12-01) -
Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation
by: Yaw-Wen Hsu, et al.
Published: (2021-01-01) -
Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases
by: Jannis Wißfeld, et al.
Published: (2024-03-01) -
Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments
by: Elena Gianchecchi, et al.
Published: (2021-05-01)